Penn Center for Innovation

Pinpoint Therapeutics targets COVID-19 with new autophagy pathway

Posted on April 3, 2020 — Jessica Jones Gupta

Pinpoint Therapeutics believes that its approach to treat therapy-resistant cancers also may be effective against COVID-19.

The molecule Pinpoint is developing, dimeric chloroquine, targets PPT1, an enzyme in the autophagy pathway that tumors use to block therapeutics. CEO Christian Peters, M.D., Ph.D., believes targeting this pathway and, specifically, the PPT1 enzyme, could prevent the COVID-19 virus from entering cells to cause infections.

Read More on BioSpace

Category: external, news